Stockholm, Sweden – [Date of Publication] – Pharmaceutical company Sobi has announced encouraging results from its Phase III REDUCE-2 study evaluating the investigational gout therapy, pozdeutinurad. The trial demonstrated a significant and sustained reduction in serum urate (SU) levels, a key biomarker for gout disease severity, marking a crucial milestone for the company as it navigates the complex landscape of gout treatment. These positive findings are poised to fuel Sobi’s anticipation for the upcoming readout of its second pivotal study, REDUCE-1, which could pave the way for regulatory submissions and a potential new therapeutic option for patients suffering from inadequately controlled gout.
Gout, a debilitating form of inflammatory arthritis, affects millions worldwide, characterized by recurrent attacks of severe joint pain, swelling, and redness. The underlying cause is hyperuricemia, a condition of elevated uric acid levels in the blood, which can lead to the formation of urate crystals in the joints and surrounding tissues. Effective management of gout hinges on achieving and maintaining target SU levels, a goal that remains elusive for a substantial portion of patients currently treated with existing oral therapies. This unmet medical need underscores the significance of positive data from trials like REDUCE-2, offering a beacon of hope for improved patient outcomes.
REDUCE-2 Study: A Deep Dive into the Data
The REDUCE-2 study, a robust Phase III clinical trial (NCT06439602), enrolled 811 patients diagnosed with uncontrolled gout. Participants were randomized to receive either a 50mg or 75mg dose of pozdeutinurad, or a placebo, administered orally once daily. The study’s primary endpoint focused on achieving serum urate levels below 6mg/dL at the six-month mark.
The results, presented as late-breaking data at ACR Convergence 2026, revealed that pozdeutinurad achieved its primary endpoint with statistically significant efficacy. Specifically, 56.6% of patients in the lower-dose (50mg) pozdeutinurad cohort and 69.2% in the higher-dose (75mg) cohort achieved target SU levels. This stands in stark contrast to the placebo arm, where only 8.1% of patients met the same target.
Beyond the primary endpoint, the study also provided compelling evidence of the drug’s sustained efficacy. Pozdeutinurad demonstrated beneficial effects as early as the first month of treatment initiation, with these improvements being durably maintained for up to 12 months. This sustained reduction in blood uric acid levels is critical for preventing the progression of gout and reducing the frequency and severity of painful flares. The selective inhibition of URAT1, a key transporter responsible for uric acid reabsorption in the kidneys, is the proposed mechanism by which pozdeutinurad exerts its uricosuric effect.
Safety and Tolerability: A Critical Component of Treatment Success
Equally important to efficacy in the chronic management of gout is the safety and tolerability profile of a therapeutic agent. The REDUCE-2 study reported that pozdeutinurad was generally well-tolerated by patients. The incidence of treatment-emergent adverse events (TEAEs) was comparable across all treatment arms. Specifically, TEAEs were reported in 60.7% of patients in the low-dose pozdeutinurad group, 61.7% in the high-dose group, and 60.9% in the placebo group. This reassuring safety data suggests that pozdeutinurad may offer a favorable risk-benefit profile, potentially making it a viable long-term treatment option for gout patients.
Official Responses and Expert Opinions
The positive outcomes of the REDUCE-2 study have been met with enthusiasm from both Sobi and key opinion leaders in the rheumatology field.
Puja Khanna, an investigator in the REDUCE-2 study, highlighted the critical need for effective gout management strategies. "Achieving and maintaining target SU levels is fundamental to effective gout management, yet many patients remain inadequately controlled with currently available oral therapies, which can lead to permanent joint and tissue damage," Khanna stated. She further emphasized the significance of pozdeutinurad’s performance, noting that "as pozdeutinurad has been shown to offer durable and clinically meaningful SU-lowering benefits, alongside a safety profile comparable to placebo, the REDUCE-2 data supports the drug’s promise as a potential treatment option for patients with uncontrolled gout."
Sobi has expressed optimism regarding the findings. While specific company statements were not detailed in the provided text, the company’s forward-looking approach, as indicated by its focus on the REDUCE-1 study, suggests a strong belief in pozdeutinurad’s potential.
Implications for the Gout Market and Future Directions
The positive data from REDUCE-2 positions Sobi to make a significant impact on the gout treatment landscape, which, despite being a prevalent condition, still grapples with substantial unmet needs. The market is currently dominated by generic medications, with innovator drugs representing a small fraction of available therapies, according to GlobalData’s Pharmaceutical Intelligence Center. A successful regulatory approval for pozdeutinurad could introduce a much-needed novel option for patients who have not responded adequately to existing treatments.
Next Steps for Pozdeutinurad:
With the encouraging results from REDUCE-2 in hand, Sobi’s focus now shifts to the outcome of REDUCE-1, the company’s other pivotal Phase III study for pozdeutinurad in uncontrolled gout. A positive readout from REDUCE-1 would be a critical step towards regulatory submissions to health authorities in key markets, potentially leading to the drug’s approval for gout patients.
Broader Gout Development Landscape:
The development of new gout therapies is an active area of research and investment. Notably, biotech company Crystalys recently secured $130 million in Series B financing to advance its own investigational gout therapy, dotinurad, through clinical trials and towards commercial readiness. This influx of capital underscores the perceived potential and market opportunity within the gout therapeutic space.
Sobi’s Broader Pipeline:
Beyond pozdeutinurad, Sobi is also pursuing market approval for its investigational gout therapy, NASP (nanoencapsulated sirolimus plus pegadricase). However, this therapy faced a setback in June 2026 when it received an approval rejection from the U.S. Food and Drug Administration (FDA). The FDA cited the need for additional Chemistry, Manufacturing, and Controls (CMC) data and required Sobi to address certain deficiencies identified at a contract manufacturing facility. This highlights the rigorous regulatory hurdles that drug developers must overcome.
The success of pozdeutinurad, if further validated by REDUCE-1 and subsequent regulatory reviews, could significantly bolster Sobi’s position in the chronic disease management sector and offer a much-anticipated advancement in the treatment of uncontrolled gout, potentially improving the lives of countless patients worldwide. The company’s strategic progression through these pivotal trials demonstrates a commitment to addressing the persistent challenges faced by individuals living with this chronic and often debilitating condition.
About the Author
